Introduction
============

Vitiligo is a common pigmentary skin disorder, characterized by a total or partial loss of melanocytes from the epidermis of skin. The prevalence of vitiligo is 0.1%--4% and is estimated to be about 1% in white individuals.[@b1-ccid-11-383] The incidence of vitiligo is similar between men and women, and half of the cases occur before the age of 20 years.[@b2-ccid-11-383]

As a psycho-dermatology disease, vitiligo is one of the aspects of the new series called "secondary psychiatric disorders".[@b3-ccid-11-383] Vitiligo does not impose serious health problems for the patients, but causes serious beauty problems; meanwhile, most doctors do not assess mood and quality of life in these patients.

The psychological burden of this dermatological problem is relatively high.[@b4-ccid-11-383] Researchers report on the burden of vitiligo that \~75% of those concerned estimate their appearance as moderately to severely intolerable.[@b5-ccid-11-383] Vitiligo reduces the patients' beauty and has deep effects on their private and social life, and causes social malfunction and decreases their quality of life.[@b6-ccid-11-383] This illness lowers their self-esteem and may cause shame in social interactions.[@b7-ccid-11-383] The patients may experience emotional stress, particularly if vitiligo develops on visible areas of the body like face. Some feel embarrassed, shameful (with decreased self-confidence), depressed, or worried about how others will react.[@b7-ccid-11-383],[@b8-ccid-11-383] A study showed that more than half of the vitiligo patients declared that people stare at them, 20% said that they are labeled, and 25% said that their disease causes problems in their relationships with strangers.[@b9-ccid-11-383]

Social acceptance of chronic diseases such as vitiligo will be encouraged by social network, including family, friends, colleagues, and neighbors.[@b3-ccid-11-383] Social acceptance is a vital aspect in the life of patients with chronic diseases and may be associated with an improved prognosis.[@b10-ccid-11-383] Furthermore, some studies have mentioned the importance of social acceptance in the quality of life of the patients,[@b11-ccid-11-383] while some patients complain that society does not accept them because of their appearance.[@b12-ccid-11-383] It seems that these patients are not properly supported by their families or society.[@b12-ccid-11-383]

Based on the fact that social acceptance in the patients is dependent on social culture, the aim of this study was to determine social acceptance of vitiligo patients in Rafsanjan, a city in Iran.

Methods
=======

This cross-sectional study was done on the vitiligo patients (n=150) referred to the dermatology clinics in Rafsanjan. Among the 150 patients referred to the dermatology clinic, 126 patients responded to the questionnaire; the response rate was 84%. The inclusion criteria were the patients should be suffering from vitiligo and referred to the dermatology clinic and have the ability to understand the concept of questionnaires. Exclusion criterion was unwillingness to participate in the research.

Data gathering tools
--------------------

### Marlowe--Crowne Social Desirability Scale (MC-SDS) for assessing social acceptance

MC-SDS questionnaire is one of the most widely used scales for detecting social desirability. MC-SDS consists of 33 items with 2 options for each item, yes (1) or no (0). Total score, which is the sum of all scores, was calculated and ranges from 0 to 33; scores between 0 and 8, 9 and 19, and 20 and 33 indicate low, moderate, and high levels of social desirability, respectively.

Marlowe--Crowne Social Desirability scale achieves an acceptable internal consistency coefficient of 0.88 and has reported 0.89 for reliability of retest.[@b13-ccid-11-383]

### Inventory of demographic characteristics

This inventory included demographic characteristics such as gender, marital status, education, duration of illness, family history, and location of the lesion.

Statistical analysis
--------------------

Descriptive statistics are presented as frequency and percentage or mean ± standard deviation (SD). The data were analyzed with independent *t*-test and ANOVA. *P*-values less than 0.05 were considered significant. Data analyses were performed using SPSS-19 software.

Ethics
------

All participants provided written informed consent. In the case of subjects under the age of 18 years, confirmation of written informed consent from the parents or legal guardians was also obtained. The study was approved by the ethics committee board of Rafsanjan University of Medical Sciences.

Results
=======

This cross-sectional study was conducted on 126 patients with vitiligo (43 men and 83 women). The mean and SD age of the patients was 27.56±10.53 years (range 13--60 years), and the average duration of the disease was 7.27±7.76 years. In terms of educational status, most patients had diploma (56.3%, N=71) and primary education (21.4%, N=27). In terms of family history, the majority of patients had no positive family history (88.1%) for vitiligo. About 70.6% (89 patients) had diffuse lesions, 10.3% (13 patients) had lesions on the extremities, and 7.1% (9 patients) had lesions on their face. Other demographic characteristics of participants are presented in [Table 1](#t1-ccid-11-383){ref-type="table"}.

The mean score of social acceptance in the patients was 13.51±7.08. The average scores for social acceptance with regard to different subgroups of gender, marital status, educational level, location of lesion, family history, and time since the occurrence of the disease are displayed in [Table 2](#t2-ccid-11-383){ref-type="table"}.

Discussion
==========

In this study, we have reported the results of a questionnaire distributed to all vitiligo patients referred to dermatology clinics in Rafsanjan, Iran. Other assessment scales have reported the adverse impact of vitiligo on patient quality of life; however, the MC-SDS has never been used in vitiligo patients. The current report is valuable as additional support that vitiligo negatively impacts patient quality of life. Also, this study focused on the social acceptance in patients with vitiligo. The mean score of social acceptance in vitiligo shows low social acceptability for this disease.

In a study by Karelson et al, the quality of life of patients with vitiligo and psoriasis, as case and healthy control groups, was compared between 2009 and 2011. The average score of the Dermatology Life Quality Index (DLQI) in the vitiligo group was 7.4, which was significantly higher than that of healthy controls (DLQI = 0.6).[@b14-ccid-11-383] The average DLQI score obtained for vitiligo patients in Karelson's study was similar to those obtained for studies performed in Belgium (DLQI = 4.9), the UK (DLQI = 4.8), and Indonesia (DLQI = 4.4).[@b15-ccid-11-383]--[@b17-ccid-11-383] In contrast, the DLQI score and social acceptance of vitiligo patients was much better in our study. Similar to our study, the mean DLQI score among the vitiligo patients was higher in Japan (9.5) when compared with studies conducted in other parts of the world.[@b18-ccid-11-383]

In a study performed by Ghajarzadeh et al in Tehran between 2009 and 2010, the quality of life in 300 patients (100 patients with alopecia areata, 100 patients with psoriasis, and 100 patients with vitiligo) was assessed, which showed that the average DLQI score in the vitiligo patients was 9.6±4.8.[@b19-ccid-11-383] Another study conducted in 2008 by Dolatshahi et al reported the DLQI score of vitiligo patients to be 16.8.[@b20-ccid-11-383]

In Karelson et al's study, the quality of life in patients with vitiligo and psoriasis, as case and healthy control groups, was compared between the years 2009 and 2011. The results showed that vitiligo has a greater impact on feelings and relationships in women. They also showed lower quality of life during the active phase/the first episode of the disease.[@b14-ccid-11-383]

In an another study that assessed the quality of life in 119 vitiligo patients and 162 psoriasis patients, women (compared to men) had significantly higher DLQI scores (45.6 vs 13.3), and gender was associated with DLQI score only in psoriasis patients.[@b18-ccid-11-383] However, in the study by Ghajarzadeh et al, women had a higher DLQI score compared with men.[@b19-ccid-11-383] Wang et al showed that patients with vitiligo feel embarrassed and, in the selection of clothing, have serious concerns about covering skin imperfections.[@b20-ccid-11-383], [@b21-ccid-11-383]

Conclusion
==========

This study indicates that certain groups of patients with vitiligo are at greater risk of experiencing a low acceptance and quality of life. Hence, it can be inferred that these patients require more serious efforts to treat the disease. Accordingly, it seems that the psychological interventions in patients who experience a worse quality of life are very important.

We acknowledge all patients with vitiligo who agreed to participate in this survey.
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###### 

Characteristics of participants in the study of vitiligo and social acceptance

  Characteristics   N    \%
  ----------------- ---- ------
  Gender                 
   Men              43   34.1
   Women            83   65.9
  Marital status         
   Married          56   44.4
   Single           60   47.6
   Divorced         10   8
  District               
   City             93   74.6
   Village          23   19
   Countryside      10   6.4

###### 

Maximum, minimum, mean, and standard deviation of social acceptance score based on demographic variables

  Variables                     Social acceptance (mean ± SD)   Minimum   Maximum   *P*-value
  ----------------------------- ------------------------------- --------- --------- -------------------------------------------------------
  Age (years)                                                                       
   13--22                       8.65± 6.70                      1         33        \<0.001[\*\*](#tfn2-ccid-11-383){ref-type="table-fn"}
   23--32                       13.86±5.05                      7         29        
   33--42                       16.91±6.37                      6         30        
   43--52                       20.25±4.57                      15        25        
   \>53                         24.60±6.88                      18        33        
  Gender                                                                            
   Men                          15.27±7.68                      1         33        0.044[\*](#tfn1-ccid-11-383){ref-type="table-fn"}
   Women                        12.60±6.62                      1         33        
  Marital status                                                                    
   Single                       9.86±5.81                       1         33        0.001[\*\*](#tfn2-ccid-11-383){ref-type="table-fn"}
   Married                      17.58±6.51                      1         33        
   Divorced                     12.60 ± 4.88                    7         22        
  Education level                                                                   
   Primary                      12.59±10.63                     1         33        0.850
   Higher                       14.75±8.39                      6         30        
   Diploma                      13.39±5.99                      1         30        
   BSc                          14.57±3.77                      9         23        
   MSc or higher                17                              17        17        
  Location of lesion                                                                
   Face                         7.66±4.30                       1         13        \<0.001[\*\*](#tfn2-ccid-11-383){ref-type="table-fn"}
   Neck                         7.85±5.01                       1         13        
   Extremities                  18.38±10.09                     1         33        
   Trunk                        17.87±8.80                      5         33        
   Diffuse                      13.44±6.04                      7         31        
  Family history                                                                    
   Positive                     15.46±6.39                      7         27        0.258
   Negative                     13.25±7.16                      1         33        
  Duration of disease (years)                                                       
   \<5                          10.32±5.94                      1         33        0.001[\*\*](#tfn2-ccid-11-383){ref-type="table-fn"}
   6--10                        13.96±6.12                      1         27        
   11--15                       18.50±7.62                      8         30        
   \>15                         15.94±4.67                      7         25        

**Notes:**

*P*\<0.05;

*P*≤0.001.
